NEW YORK CITY, NY / ACCESS Newswire / October 25, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE:MOH).â?¯â?¯ Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are […]
(Stockholm:SOBI), NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still's disease across MAS subtypes, including in those with recurrent disease Discussion of the first ever international, randomized, multicentre, double-blind, placebo-controlled phase 2 dose finding trial of Vonjo(R) (pacritinib) in
(NASDAQ:CGEM), CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, will present new preclinical data for CLN-978,
Data presented at ACR Convergence 2025 highlight Sobi's commitment to advancing care across rare and underserved inflammatory conditions GlobeNewswire October 25, 2025 NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still's disease across MAS subtypes, including in those with
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 GlobeNewswire October 25, 2025 CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc.
NEW YORK CITY, NY / ACCESS Newswire / October 25, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fortinet, Inc. ("Fortinet" or the "Company") (NASDAQ:FTNT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK CITY, NY / ACCESS Newswire / October 25, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Semler Scientific, Inc. ("Semler" or the "Company") (NASDAQ:SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are
TheDigitalHotelier(TDH), the leading all-in-one platform for hospitality operational optimization, today announced its aggressive entry into the North American and Latin American (LATAM) markets. Headquartered in Dubai,TDH is solidifying its position as the dominant force in streamlining hotel operations, including housekeeping, staff training and management, and utility-cost mitigation through proactive alerts. https://mma.prnewswire.com/media/2805109/Ad_Image.jpg The key issue is
— Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across measures of peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis – indicating sustained inflammation control — Sustained clinical response to stringent endpoints in half of patients with axial spondyloarthritis (nr-axSpA and AS):
NEW YORK CITY, NY / ACCESS Newswire / October 25, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Quanex Building Products Corporation ("Quanex" or the "Company") (NYSE:NX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail